The growing evidence supporting both pharmacological induction and exogenous delivery of HSPB8 underscores its potential as a therapeutic target in diverse proteinopathies and neurodegenerative disorders and remains an important future direction for the field. Here, HSPB8 is linked to proteostasis deficiencies.